Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Sees Significant Decrease in Short Interest

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) was the recipient of a large decline in short interest during the month of March. As of March 15th, there was short interest totalling 159,600 shares, a decline of 96.2% from the February 28th total of 4,160,000 shares. Based on an average daily volume of 936,100 shares, the days-to-cover ratio is presently 0.2 days. Currently, 14.9% of the company’s stock are short sold.

Hepion Pharmaceuticals Price Performance

HEPA stock traded down $0.03 during trading on Wednesday, hitting $0.69. 2,502,279 shares of the stock traded hands, compared to its average volume of 255,378. The stock has a market cap of $95,215.00, a price-to-earnings ratio of -0.16 and a beta of 1.62. Hepion Pharmaceuticals has a 1 year low of $0.55 and a 1 year high of $145.00. The firm’s 50 day moving average is $7.46 and its two-hundred day moving average is $22.90.

Institutional Investors Weigh In On Hepion Pharmaceuticals

A hedge fund recently bought a new stake in Hepion Pharmaceuticals stock. Anson Funds Management LP acquired a new stake in Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 231,849 shares of the company’s stock, valued at approximately $155,000. Anson Funds Management LP owned approximately 3.33% of Hepion Pharmaceuticals at the end of the most recent quarter. 17.24% of the stock is currently owned by institutional investors and hedge funds.

Hepion Pharmaceuticals Company Profile

Hepion Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms.